Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 19;9(9):e19163.
doi: 10.1016/j.heliyon.2023.e19163. eCollection 2023 Sep.

Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms

Tiantian Meng  1   2 , Jingyi Ding  1 , Shujie Shen  3 , Yingzhi Xu  4 , Peng Wang  5   6 , Xinbin Song  7 , Yixiang Li  7 , Shangjin Li  1 , Minjie Xu  4 , Ziyu Tian  8 , Qingyong He  1
Affiliations
Review

Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms

Tiantian Meng et al. Heliyon. .

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide and become a major global public health concern. Although novel investigational COVID-19 antiviral candidates such as the Pfizer agent PAXLOVID™, molnupiravir, baricitinib, remdesivir, and favipiravir are currently used to treat patients with COVID-19, there is still a critical need for the development of additional treatments, as the recommended therapeutic options are frequently ineffective against SARS-CoV-2. The efficacy and safety of vaccines remain uncertain, particularly with the emergence of several variants. All 10 versions of the National Health Commission's diagnosis and treatment guidelines for COVID-19 recommend using traditional Chinese medicine. Xuanfei Baidu Decoction (XFBD) is one of the "three Chinese medicines and three Chinese prescriptions" recommended for COVID-19. This review summarizes the clinical evidence and potential mechanisms of action of XFBD for COVID-19 treatment. With XFBD, patients with COVID-19 experience improved clinical symptoms, shorter hospital stay, prevention of the progression of their symptoms from mild to moderate and severe symptoms, and reduced mortality in critically ill patients. The mechanisms of action may be associated with its direct antiviral, anti-inflammatory, immunomodulatory, antioxidative, and antimicrobial properties. High-quality clinical and experimental studies are needed to further explore the clinical efficacy and underlying mechanisms of XFBD in COVID-19 treatment.

Keywords: COVID-19; Chinese herbal medicine; Clinical efficacy; Mechanism; SARS-CoV-2; Xuanfei Baidu decoction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
PRISMA flowchart of the study selection process.
Fig. 2
Fig. 2
The processed raw materials of the Xuanfei Baidu Decoction (the images are collected from the Internet, with no conflict of interest).
Fig. 3
Fig. 3
Anti-SARS-CoV-2 mechanisms of Xuanfei Baidu Decoction and its traditional Chinese medicine herbs.
Fig. 4
Fig. 4
Anti-inflammatory effects and immunomodulatory effects of Xuanfei Baidu decoction and its traditional Chinese medicine herbs.
Fig. 5
Fig. 5
Antioxidative properties of Xuanfei Baidu decoction and its traditional Chinese medicine herbs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K. First case of 2019 novel coronavirus in the United States, N. Engl. J. Med. 2020;382(10):929–936. - PMC - PubMed
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382(8):727–733. - PMC - PubMed
    1. Livingston E., Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. Jama. 2020;323(14):1335. - PubMed
    1. Sun J., Shen H., Shao L., Teng X., Chen Y., Liu X., Yang Z., Shen Z. HIF-1 alpha overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis. Stem Cell Res. Ther. 2020;11(1):373. - PMC - PubMed
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. - PMC - PubMed

LinkOut - more resources